These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 14716911)

  • 1. [Focus on smoking cessation or drugs?].
    Lindberg M
    Ugeskr Laeger; 2003 Dec; 165(50):4872; author reply 4872-3. PubMed ID: 14716911
    [No Abstract]   [Full Text] [Related]  

  • 2. [Focus on smoking cessation or drugs--2].
    Lindberg M
    Ugeskr Laeger; 2004 Jan; 166(3):178-9; author reply 179. PubMed ID: 14870652
    [No Abstract]   [Full Text] [Related]  

  • 3. Spending decisions for tobacco-related disease treatment and tobacco control: an example and a solution.
    Thomson G; Wilson N
    N Z Med J; 2005 Feb; 118(1210):U1337. PubMed ID: 15776107
    [No Abstract]   [Full Text] [Related]  

  • 4. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Walk-in spirometry pilot project for discovering of early chronic obstructive pulmonary disease].
    Løkke A; Christensen LB; Fuglsang C
    Ugeskr Laeger; 2009 Oct; 171(43):3083-8. PubMed ID: 19852895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determining the possibility of collecting reliable data for use in decision making in health care on the example of cost-effectiveness analysis of methods used in smoking cessation].
    Bała M
    Przegl Lek; 2004; 61(10):1180-3. PubMed ID: 15794284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of chronic obstructive pulmonary disease and its effects on managed care.
    Mapel D; Chen JC; George D; Halbert RJ
    Manag Care Interface; 2004 Apr; 17(4):61-6. PubMed ID: 15108761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity.
    Sin DD; Golmohammadi K; Jacobs P
    Am J Med; 2004 Mar; 116(5):325-31. PubMed ID: 14984818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease modification in chronic obstructive pulmonary disease.
    Anzueto A
    Clin Chest Med; 2007 Sep; 28(3):609-16,vii. PubMed ID: 17720047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
    Chiang CH
    Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
    Simoens S; Decramer M; Laekeman G
    Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease.
    Lee TA; Weiss KB; Sullivan SD
    Am J Med; 2004 Oct; 117(8):618; author reply 618-9. PubMed ID: 15465515
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs for chronic obstructive pulmonary disease.
    Treat Guidel Med Lett; 2007 Nov; 5(63):95-100. PubMed ID: 17938609
    [No Abstract]   [Full Text] [Related]  

  • 16. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
    Menzin J; Lines LM; Marton J
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):257-64. PubMed ID: 19527098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Smoking cessation and chronic obstructive pulmonary disease].
    Møller AM; Tønnesen H
    Ugeskr Laeger; 2004 Oct; 166(42):3695-7. PubMed ID: 15508287
    [No Abstract]   [Full Text] [Related]  

  • 18. Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden.
    Tunsäter A; Moutakis M; Borg S; Persson U; Strömberg L; Nielsen AL
    Health Policy; 2007 May; 81(2-3):309-19. PubMed ID: 16904788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
    Gagnon YM; Levy AR; Spencer MD; Hurley JS; Frost FJ; Mapel DW; Briggs AH
    Respir Med; 2005 Dec; 99(12):1534-45. PubMed ID: 16291076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in health care costs before and after smoking cessation.
    Fishman PA; Thompson EE; Merikle E; Curry SJ
    Nicotine Tob Res; 2006 Jun; 8(3):393-401. PubMed ID: 16801297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.